In This Article: SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8 , 2025. On the same day, at 1:30 pm Pacific Time ( 4:30 pm Eastern Time ) Jacob Thaysen , PhD, Chief Executive Officer, and Ankur Dhingra , Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time ( 4:30 pm Eastern Time ) on Thursday, May 8, 2025 . Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link - https://illumina-earnings-call-q1-2025.open-exchange.net/registration . To ensure timely connection, please join at least ten minutes before the scheduled start of the call. A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter) , Facebook , LinkedIn , Instagram , TikTok , and YouTube. Investors: Brian Blanchett +1.858.291.6421 ir@illumina.com Media: Bonny Fowler +1.740.641.5579 pr@illumina.com Cision View original content: https://www.prnewswire.com/news-releases/illumina-to-announce-first-quarter-2025-financial-results-on-thursday-may-8-2025-302425956.html SOURCE Illumina, Inc. Cision
Illumina is a California-based biotechnology company that designs and develops products such as sequencing reagents and microarray kits for the life sciences industry.